Skip to main content

Table 5 LS-SBA - progression free survival by prognostic factors in only patients who received first-line chemotherapy

From: Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience

   Number events/Number subjects 1 Year survival(95% CI) Hazard ratio(95% CI) p-value
Gender Male 20/24 20.2 (2.8 – 37.6) 1.69 (0.88 – 3.24) 0.115
  Female 17/22 39.4 (17.3 – 61.5) -  
Primary tumour Duodenum 28/34 23.8 (7.5 – 40.1) - (0.179)
  Jejunum 5/7 28.6 (0 – 62.1) 0.50 (0.19 – 1.33) 0.164
  Ileum 4/5 60.0 (17.1 – 100) 0.45 (0.15 – 1.32) 0.146
Disease status Locally Advanced 2/2 50.0 (0 – 100) -  
  Metastatic 35/44 28.4 (13.9 – 42.9) 1.35 (0.32 – 574) 0.683
Chemo 1ST line Doublet 15/18 25.0 (4.2 – 45.8) -  
  Triplet 19/23 34.1 (12.5 – 55.7) 1.05 (0.53 – 2.09) 0.884
Chemo 2nd line No 18/17 27.9 (8.1 – 47.7) -  
  Yes 19/19 31.6 (10.6 – 52.6) 1.17 (0.61 – 2.24) 0.633
Small Bowel Obstruction None 22/28 19.8 (2.7 – 36.9) -  
  Present 6/8 42.9 (6.2 – 79.6) 0.69 (0.27 – 1.75) 0.437
Weight loss None 15/23 28.6 (6.1 – 51.1) -  
  Present 13/13 23.1 (0 – 46.0) 1.29 (0.61 – 2.73) 0.499
CEA at baseline Normal 6/9 66.7 (35.9 – 97.5) -  
  Abnormal 25/27 12.8 (0 – 26.3) 3.18 (1.23 – 8.19) 0.017
Hemoglobin Normal 8/10 48.0 (15.9 – 80.1) -  
  Abnormal 25/29 20.5 (4.6 – 36.4) 1.88 (0.83 – 4.24) 0.130
Albumin Normal 17/22 44.4 (22.1 – 66.7) -  
  Abnormal 16/17 6.7 (0 – 19.4) 2.29 (1.12 – 4.66) 0.023
LDH Normal 14/18 34.4 (10.9 – 57.9) -  
  Abnormal 15/16 20.0 (0 – 40.2) 1.48 (0.70 – 3.15) 0.310
Alk.Ph Normal 18/23 34.8 (13.0 – 56.6) -  
  Abnormal 15/16 18.8 (0 – 38.0) 1.32 (0.66 – 2.62) 0.437
ALT Normal 25/30 31.2 (13.6 – 48.8) -  
  Abnormal 7/8 16.7 (0 – 45.7) 1.95 (0.82 – 4.61) 0.131
Platelets Normal 17/24 43.6 (21.8 – 65.4) -  
  Abnormal 17/17 11.8 (0 – 27.1) 2.32 (1.14 – 4.73) 0.020